Diffusion-related mri parameters for assessing early treatment response of liver metastases to cytotoxic therapy in colorectal cancer

American Journal of Roentgenology

Volumn 207, Issue 3, 2016, Pages W26-W32

  Kim, Jung Hoon ^a,b   Joo, Ijin ^a   Kim, Tae Yong ^a   Han, Sae Won ^a   Kim, Yong Jae ^c   Lee, Jeong Min ^a,b   Han, Joon Koo ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

DWI; Dynamic contrast enhanced MRI; Focal liver lesion; Intravoxel incoherent motion; Therapeutic response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; CONTRAST MEDIUM;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EARLY INTERVENTION; EXTRAVASCULAR EXTRACELLULAR VOLUME FRACTION; FEMALE; HUMAN; INTRAVOXEL INCOHERENT MOTION; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERFUSION FRACTION; PHYSICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PSEUDODIFFUSION COEFFICIENT; RADIOLOGICAL PARAMETERS; TREATMENT RESPONSE; VOLUME TRANSFER CONSTANT; COLORECTAL TUMOR; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

AGED; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84983261942     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.15.15683     Document Type: Article

References (30)

1. de Gramont Ad, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947
2. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-914
4. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14:13-16
5. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-520; discussion, 520-522
6. Guglielmi AP, Sobrero AF. Second-line therapy for advanced colorectal cancer. Gastrointest Cancer Res 2007; 1:57-63
7. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
11. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248:894-900
12. Dudeck O, Zeile M, Wybranski C, et al. Early prediction of anticancer effects with diffusionweighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 2010; 20:2699-2706
13. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR 2007; 188:1001-1008
14. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964
15. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96:189-195
16. Türkbey B, Thomasson D, Pang Y, Bernardo M, Choyke PL. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol 2010; 16:186-192
17. Lemke A, Laun FB, Klau M, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol 2009; 44:769-775
18. Lemke A, Laun FB, Simon D, Stieltjes B, Schad LR. An in vivo verification of the intravoxel incoherent motion effect in diffusion-weighted imaging of the abdomen. Magn Reson Med 2010; 64:1580-1585
19. Orton MR, d'Arcy JA, Walker-Samuel S, et al. Computationally efficient vascular input function models for quantitative kinetic modelling using DCE-MRI. Phys Med Biol 2008; 53:1225-1239
20. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10:223-232
21. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18:299-304
22. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237:492-499
23. Le Bihan D. Intravoxel incoherent motion imaging using steady-state free precession. Magn Reson Med 1988; 7:346-351
24. Le Bihan D. Intravoxel incoherent motion perfusion MR imaging: a wake-up call. Radiology 2008; 249:748-752
25. Doblas S, Wagner M, Leitao HS, et al. Determination of malignancy and characterization of hepatic tumor type with diffusion-weighted magnetic resonance imaging: comparison of apparent diffusion coefficient and intravoxel incoherent motion-derived measurements. Invest Radiol 2013; 48:722-728
26. Chiaradia M, Baranes L, Nhieu JT, et al. Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis? J Magn Reson Imaging 2014; 39:317-325
27. Le Bihan D, Turner R. The capillary network: a link between IVIM and classical perfusion. Magn Reson Med 1992; 27:171-178
28. Powers TA, Lorenz C, Holburn G, Price R. Renal artery stenosis: in vivo perfusion MR imaging. Radiology 1991; 178:543-548
29. Wirestam R, Borg M, Brockstedt S, Lindgren A, Holtås S, Ståhlberg F. Perfusion-related parameters in intravoxel incoherent motion MR imaging compared with CBV and CBF measured by dynamic susceptibility-contrast MR technique. Acta Radiol 2001; 42:123-128
30. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010; 31:589-600